Atea Pharmaceuticals Stock Price, News & Analysis
AVIR
NASDAQ
Company Description
Welcome to the overview page for Atea Pharmaceuticals (AVIR), where you can find comprehensive stock information and company updates.
Explore the latest news on strategic partnerships, quarterly and annual financial results, and regulatory filings including SEC reports and insider transactions.
Visualize performance trends using the interactive price chart, and keep track of upcoming events such as earnings calls, dividend dates, and investor conferences.
Stock Performance
Latest News
SEC Filings
Financial Highlights
$0
Revenue (TTM)
-$168,385,000
Net Income (TTM)
-$2.00
-$135,499,000
Operating Cash Flow
24.85
-$192,950,000
Upcoming Events
APR
01
April 1, 2026 - June 30, 2026
Clinical
C-BEYOND topline data
Topline results for C-BEYOND Phase 3 program
APR
01
April 1, 2026 - June 30, 2026
Clinical
C-FORWARD enrollment completion
Expected completion of C-FORWARD Phase 3 enrollment
APR
01
April 1, 2026 - June 30, 2026
Clinical
HEV Phase 1 start
Initiation of Phase 1 studies for HEV leads AT-587 and AT-2490
MAY
01
May 1, 2026 - August 31, 2026
Clinical
C-BEYOND topline results
Phase 3 North America trial topline results for bemnifosbuvir/ruzasvir; >880 patients
MAY
01
May 1, 2026 - August 31, 2026
Clinical
C-FORWARD enrollment completion
Enrollment expected for Phase 3 outside North America (~880 patients, ~120 sites)
OCT
01
October 1, 2026 - December 31, 2026
Clinical
C-FORWARD topline results
Topline results anticipated for Phase 3 C-FORWARD outside North America
OCT
01
October 1, 2026 - December 31, 2026
Clinical
C-FORWARD topline data
Topline results for C-FORWARD Phase 3 program
Short Interest History
Last 12 Months
Loading short interest data...
Days to Cover History
Last 12 Months
Loading days to cover data...
Frequently Asked Questions
What is the current stock price of Atea Pharmaceuticals (AVIR)?
The current stock price of Atea Pharmaceuticals (AVIR) is $3.57 as of December 31, 2025.
What is the market cap of Atea Pharmaceuticals (AVIR)?
The market cap of Atea Pharmaceuticals (AVIR) is approximately 277.4M. Learn more about what market capitalization means .
What is the revenue (TTM) of Atea Pharmaceuticals (AVIR) stock?
The trailing twelve months (TTM) revenue of Atea Pharmaceuticals (AVIR) is $0.
What is the net income of Atea Pharmaceuticals (AVIR)?
The trailing twelve months (TTM) net income of Atea Pharmaceuticals (AVIR) is -$168,385,000.
What is the earnings per share (EPS) of Atea Pharmaceuticals (AVIR)?
The diluted earnings per share (EPS) of Atea Pharmaceuticals (AVIR) is -$2.00 on a trailing twelve months (TTM) basis. Learn more about EPS .
What is the operating cash flow of Atea Pharmaceuticals (AVIR)?
The operating cash flow of Atea Pharmaceuticals (AVIR) is -$135,499,000. Learn about cash flow.
What is the current ratio of Atea Pharmaceuticals (AVIR)?
The current ratio of Atea Pharmaceuticals (AVIR) is 24.85, indicating the company's ability to pay short-term obligations. Learn about liquidity ratios.
What is the operating income of Atea Pharmaceuticals (AVIR)?
The operating income of Atea Pharmaceuticals (AVIR) is -$192,950,000. Learn about operating income.